[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604610":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":24,"centralContacts":27,"locations":33,"responsibleParty":50,"collaborators":24,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":24,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":24,"enrollmentInfo":61,"targetDuration":24,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":36,"whyStopped":24,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vitrectomy + Direct Intra-Arterial Microneedle Thrombolysis + Standard Care","EXPERIMENTAL","The patients will receive standard pars plana vitrectomy (PPV) combined with direct intra-arterial microneedle thrombolysis under microscopic visualization, in addition to standard clinical treatment for RAO. A 47G microneedle will be used to deliver thrombolytic agent intra-arterially per protocol.",[13],"Procedure: Standard Clinical Care Only",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard Clinical Care Only","ACTIVE_COMPARATOR","The patients will receive standard clinical treatment for RAO without vitrectomy or intra-arterial microneedle thrombolysis.",[19],"Procedure: Vitrectomy + Direct Intra-Arterial Microneedle Thrombolysis + Standard Care",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"PROCEDURE",[15],null,{"type":22,"name":15,"description":17,"armGroupLabels":26,"otherNames":24},[9],[28],{"name":29,"role":30,"phone":31,"phoneExt":24,"email":32},"Jian Ma, MD.","CONTACT","+8618858299889","jian_ma@zju.edu.cn",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Eye Center of the Second Affiliated Hospital of Zhejiang University","RECRUITING","Hangzhou","Zhejiang","310058","China","CN",{"type":43,"coordinates":44},"Point",[45,46],120.16142,30.29365,{"lat":46,"lon":45},[49],{"name":29,"role":30,"phone":31,"phoneExt":24,"email":32},{"type":51,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100604610","microneedle-intra-arterial-injection-for-retinal-artery-occlusion-100604610",false,"NCT07151755","Microneedle Intra-Arterial Injection for Retinal Artery Occlusion","Microneedle Intra-Arterial Injection With Pars Plana Vitrectomy for Acute Retinal Artery Occlusion: A Prospective Clinical Trial","Inclusion Criteria:\n\n* Age ≥18 years\n* Acute non-arteritic retinal artery occlusion (RAO), including: Central retinal artery occlusion (CRAO), or Branch retinal artery occlusion (BRAO) involving the macula or causing severe visual loss; defined as symptom onset ≤7 days and confirmed by exam ± imaging (FFA\u002FOCT)\n* Best-corrected visual acuity (BCVA) \\\u003C0.5 (decimal)\n\nExclusion Criteria:\n\n* Active bleeding disorder, or significant bleeding within the past 3 months, or bleeding diathesis\n* Severe hypertension: SBP \\>185 mmHg or DBP \\>110 mmHg\n* Severe coagulopathy or ongoing therapeutic anticoagulation\n* Ischemic stroke within the past 3 months\n* Severe, unstable systemic disease rendering surgery or anesthesia risk unacceptable\n* Known hypersensitivity to thrombolytic agents or any study medications\u002Fmaterials\n* Active ocular infection\n* Vitreous hemorrhage\n* Retinal arteritis\n* Pregnancy or lactation","ALL","18 Years",{"count":62,"type":63},24,"ESTIMATED","INTERVENTIONAL",[66],"NA","This prospective interventional study evaluates the efficacy and safety of direct intra-arterial microneedle injection combined with pars plana vitrectomy for acute retinal artery occlusion (including central retinal artery occlusion \\[CRAO\\] and branch retinal artery occlusion \\[BRAO\\] involving the macula or causing severe visual loss). The primary endpoint is best-corrected visual acuity (BCVA, LogMAR) at 1 month. Secondary objectives include assessing the effect of treatment timing and monitoring longitudinal changes in visual function and retinal structure over 12 months.",[69],"Central Retinal Artery Occlusion",[71,72,73],"central retinal artery occlusion","microneedle","thrombolysis","2025-08-25",{"date":76,"type":77},"2025-09-03","ACTUAL",{"date":79,"type":63},"2025-09-01",{"date":81,"type":63},"2027-07-31",{"name":5,"class":6},1]